Business
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2021 Results
Total net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nTotal net sales of $67.4 million for the full year, up 14% from the prior year, with $56.7 million from Tru Niagen® and gross margin of 61.5%. Total net sales of $17.8 million for the three months ended December 31, 2021, up 15% from the prior year quarter.\n\n LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2021 financial results.\n\nFourth Quarter 2021 and Recent Highlights\n\n\nTotal net sales were $17.8 million, up 15% year over year.\n\n\nTru Niagen® net sales were $14.1 million, a 14% increase year over year.\n\n\nGross margin was 61.2%, up 20 basis points year over year.\n\n\nNet loss was $5.3 million or $0.08 loss per share, an improvement of $0.02 per share year over year.\n\n\nIn January 2022, announced a supply agreement with Designs for Health to sell Niagen® in specially-formulated products, available exclusively through the company’s extensive healthcare practitioner network.\n\n\nThe ChromaDex External Research Program (CERP) celebrates 100 published peer-reviewed studies on Niagen® and other ingredients. This research conducted by independent investigators has expanded the understanding of nicotinamide riboside (NR) in key health areas including Ataxia-telangiectasia, skeletal muscle, liver health, and heart failure.\n\n\nClinical study published in Cell Metabolism finds that NR supplementation significantly increased cerebral NAD levels, and decreased levels of inflammatory cytokines in Parkinson’s Disease (PD) patients, building on positive preclinical research supporting NR’s positive impact on neurodegenerative diseases. Further studies are underway to understand the role of NR supplementation in Parkinson’s patients.\n\n\nNew U.S. continuation patent reinforces ChromaDex’s intellectual property portfolio of over 40 patents on NR and other NAD precursors by adding protection of a novel manufacturing process of NR and its various salt forms.\n\n\nFull Year 2021 Highlights\n\n\nDelivered on latest financial outlook to investors across all metrics. Slightly better than target on research and development, general and administrative expense.\n\n\nTotal net sales of $67.4 million, up 14% from $59.3 million year over year.\n\n\nTru Niagen® net sales of $56.7 million, a 20% increase from $47.1 million year over year.\n\n\nGross margins of 61.5%, a 200 bas...